Phase 1 clinical study set to commence H1 2024 Pre-clinical data presented demonstrates robust anti-tumor activity in solid tumor models “Pre-clinical data generated to-date demonstrates that CRB-601 ...
The rule was a change from prior law, known as the time of decision rule, which allowed municipalities to make changes to ordinances and or to disallow permitted uses during the pendency of a hearing ...
NORWOOD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today ...
Phase 1 clinical study set to commence H1 2024 Pre-clinical data presented demonstrates robust anti-tumor activity in solid tumor models NORWOOD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Corbus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results